ExCellThera announces new publication showing its ECT-001 cell therapy improves transplant access for all patients

ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today the publication of a scientific article entitled “UM171 expansion of cord blood improves donor availability and HLA matching for all patients, including minorities”. The study by Dumont-Lagacé et al., was recently published in the peer-reviewed medical journal Transplantation and Cellular Therapy.